We have quantified optical contrast of various tumor type (N=34) with a clinical diffuse optical tomography system. Also, we have monitored neoadjuvant chemothe rapy response which agreed well with MRI.
The physiological/optical parameters accessible by the diffuse optical methods hold a great potential to complement the existing breast cancer diagnostic tools. From intrinsic optical properties, the diffuse optical spectroscopy (DOS) and tomography (DOT) provide oxygenated and deoxygenated hemoglobin, water and lipid concentration and scattering parameters. The diffuse correlation spectroscopy (DCS) provides information on blood flow. Additional information and enhancement of contrast may be possible with injection of contrast agent (such as Indocyanine Green).
With a clinical DOT system, we have quantified optical contrast of various tumor type (e.g. fibroadenoma, in-situ and invasive carcinoma) with respect to surrounding breast tissue (N=34). Preliminary results show significant distinction between fibroadenoma and invasive carcinoma in optical contrast. We have utilized DOT and DCS system to monitor neoadjuvant chemotherapy response of patients with locally advanced breast cancer. The optical contrast of tumor decreases with treatment progress in general, in good correlation with dynamic-contrast-enhanced MRI. Notably, relative blood flow between tumor and healthy tissue (new optical parameter accessible by DCS) show robust changes with treatment even in early stage. 
